mRNA Vaccines for Colorectal Cancer: Antigen Design, Nanodelivery, and Clinical Translation

Messenger RNA (mRNA) vaccines offer a flexible approach to colorectal cancer (CRC) immunotherapy, with applications ranging from postoperative residual disease to metastatic cancer. This narrative review examines antigen selection, RNA engineering, nanodelivery, and clinical development, drawing on literature available through 21 October 2026. Tumor-associated antigens, shared driver mutations, and personalized neoantigens offer different advantages in population coverage, specificity, and manufacturing. Their activity also depends on RNA chemistry and carrier design, including lipid composition, endosomal release, APC targeting, tissue distribution, stability, and repeated dosing. Early clinical studies have demonstrated antigen-specific T-cell responses in selected patients, while randomized melanoma data provide a benchmark for combining vaccination with checkpoint blockade. The termination of the CRC adjuvant autogene cevumeran monotherapy trial highlights the difficulty of translating immune priming into recurrence prevention. Antigen heterogeneity, impaired HLA presentation, stromal exclusion, and liver-associated immune suppression remain important barriers in CRC. Advances in neoantigen prediction, self-amplifying RNA, and mechanism-based combinations may improve vaccine design, but their clinical value will depend on disease-specific trials that account for manufacturing feasibility and established oncological endpoints. The available evidence remains heterogeneous, with small CRC cohorts and limited randomized outcomes; the non-systematic search also introduces potential selection bias.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-11-18
DOI
https://doi.org/10.3390/vaccines14110994
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

mRNA Vaccines for Colorectal Cancer: Antigen Design, Nanodelivery, and Clinical Translation

Cao Rong-zhe, Lei Yu, Haitong Li, Yu-Xin Cao et al.
4 links
Vaccines
Immunotherapy and Immune Responses
article

mRNA Vaccines for Colorectal Cancer: Antigen Design, Nanodelivery, and Clinical Translation

Cao Rong-zhe, Lei Yu, Haitong Li, Yu-Xin Cao, Li Gao, Jin Li, Yang-Yi-Yi Long
article en

Abstract

Messenger RNA (mRNA) vaccines offer a flexible approach to colorectal cancer (CRC) immunotherapy, with applications ranging from postoperative residual disease to metastatic cancer. This narrative review examines antigen selection, RNA engineering, nanodelivery, and clinical development, drawing on literature available through 21 October 2026. Tumor-associated antigens, shared driver mutations, and personalized neoantigens offer different advantages in population coverage, specificity, and manufacturing. Their activity also depends on RNA chemistry and carrier design, including lipid composition, endosomal release, APC targeting, tissue distribution, stability, and repeated dosing. Early clinical studies have demonstrated antigen-specific T-cell responses in selected patients, while randomized melanoma data provide a benchmark for combining vaccination with checkpoint blockade. The termination of the CRC adjuvant autogene cevumeran monotherapy trial highlights the difficulty of translating immune priming into recurrence prevention. Antigen heterogeneity, impaired HLA presentation, stromal exclusion, and liver-associated immune suppression remain important barriers in CRC. Advances in neoantigen prediction, self-amplifying RNA, and mechanism-based combinations may improve vaccine design, but their clinical value will depend on disease-specific trials that account for manufacturing feasibility and established oncological endpoints. The available evidence remains heterogeneous, with small CRC cohorts and limited randomized outcomes; the non-systematic search also introduces potential selection bias.

VaccinesVol. 14(11)
Harbin Medical University (CN), Second Affiliated Hospital of Harbin Medical University (CN)
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon